title: [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].
abstract: In March 2015, the first Advanced Prostate Cancer Consensus Conference (APCC) took place in St. Gallen. 41 experts from 17 countries reviewed important areas of controversy in advanced hormone-naive and castration-resistant prostate cancer and gave therapy recommendations. These results have been recently published in "Annals of Oncology". While most of the recommendations from St. Gallen are comprehensible, some of them need to be further discussed. Therefore, we as a German expert panel will critically debate the St. Gallen recommendations. For metastatic hormone-naive prostate cancer, continuous androgen deprivation remains the standard. There is no evidence for superiority of primary maximal androgen deprivation. Patients suitable for chemotherapy, especially in the presence of high tumour burden, should receive androgen deprivation plus taxanes upfront. In metastatic castration resistant prostate cancer, novel hormonal agents like abiraterone or enzalutamid should be the treatment of choice in the majority of patients. Taxanes should be used first-line in patients with unfavourable prognostic markers. Radium-223 is an option in symptomatic patients with bone metastases. There is first evidence that second-line hormonal treatment after first-line failure of a novel endocrine agent has a high failure rate. Cabazitaxel should be part of the treatment sequence in patients with a good performance status. Baseline staging for castration-resistant prostate cancer should include CT-abdomen/-chest and bone scan. Radiographic monitoring should be performed 2 to 3 times a year. Determination of PSA and ALP is to take place every 2 to 4 months.
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland. christian.thomas@kgu.de.
authors.forename: C
authors.initials: C
authors.lastname: Thomas
authors.affiliation: Klinik für Urologie, Universitätsklinikum Münster, Münster, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Bögemann
authors.affiliation: ATURO, Facharztzentrum für Urologie, Berlin, Deutschland.
authors.forename: F
authors.initials: F
authors.lastname: König
authors.affiliation: Klinik für Urologie, Marien-Krankenhaus Bergisch Gladbach, Bergisch Gladbach, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Machtens
authors.affiliation: Klinik für Urologie und Kinderurologie, Uniklinik Magdeburg, Magdeburg, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Schostak
authors.affiliation: Martini Klinik, Hamburg, Deutschland.
authors.forename: T
authors.initials: T
authors.lastname: Steuber
authors.affiliation: Klinik und Poliklinik für Urologie, Universitätsklinikum Köln, Köln, Deutschland.
authors.forename: A
authors.initials: A
authors.lastname: Heidenreich
mesh_terms: D006801:Humans; D008297:Male; D000726:Androgen Antagonists / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D019317:Evidence-Based Medicine; D005858:Germany; D009362:Neoplasm Metastasis; D017410:Practice Guidelines as Topic; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D014572:Urology / Q000592:standards; D003245:Consensus Statements as Topic
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids
keywords: APCCC; CRPC; Metastatic prostate cancer; Monitoring; Treatment
references.citation: Urology. 1997 Jan;49(1):71-8
references.pmid: 9000189
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: J Clin Oncol. 2008 Jan 10;26(2):242-5
references.pmid: 18182665
references.citation: Clin Genitourin Cancer. 2015 Aug;13(4):392-9
references.pmid: 25708161
references.citation: J Clin Oncol. 2008 Mar 1;26(7):1148-59
references.pmid: 18309951
references.citation: Cancer. 2014 Nov 1;120(21):3346-52
references.pmid: 24995769
references.citation: J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
references.pmid: 25234529
references.citation: N Engl J Med. 2013 Apr 4;368(14):1314-25
references.pmid: 23550669
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: Prostate. 2014 Sep;74(13):1278-85
references.pmid: 25053178
references.citation: Urology. 2010 Nov;76(5):1189-93
references.pmid: 20303155
references.citation: Eur Urol. 2015 Apr;67(4):673-9
references.pmid: 25457497
references.citation: J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68
references.pmid: 12359855
references.citation: Prostate. 2001 Jun 15;48(1):29-39
references.pmid: 11391684
references.citation: N Engl J Med. 2014 Sep 11;371(11):1028-38
references.pmid: 25184630
references.citation: Eur Urol. 2013 Jun;63(6):977-82
references.pmid: 23116658
references.citation: N Engl J Med. 2015 Aug 20;373(8):737-46
references.pmid: 26244877
references.citation: Cancer. 2002 Jul 15;95(2):361-76
references.pmid: 12124837
references.citation: Urol Oncol. 2013 Nov;31(8):1845
references.pmid: 24210084
references.citation: Eur Urol. 2014 Aug;66(2):330-6
references.pmid: 23957945
references.citation: Eur Urol. 2015 Jan;67(1):23-9
references.pmid: 25018038
references.citation: J Clin Oncol. 2013 Oct 20;31(30):3800-6
references.pmid: 24043751
references.citation: JAMA Oncol. 2015 Aug;1(5):582-91
references.pmid: 26181238
references.citation: Clin Cancer Res. 2015 May 15;21(10):2315-24
references.pmid: 25712683
references.citation: N Engl J Med. 2014 Jul 31;371(5):424-33
references.pmid: 24881730
references.citation: Crit Rev Oncol Hematol. 2015 Dec;96(3):498-506
references.pmid: 26318091
references.citation: Acta Oncol. 2015 Jul;54(7):961-70
references.pmid: 25984930
references.citation: Ann Oncol. 2015 Aug;26(8):1589-604
references.pmid: 26041764
references.citation: N Engl J Med. 2012 Sep 6;367(10):895-903
references.pmid: 22931259
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: Lancet. 2011 Mar 5;377(9768):813-22
references.pmid: 21353695
references.citation: N Engl J Med. 2013 Jul 18;369(3):213-23
references.pmid: 23863050
references.citation: J Clin Oncol. 2015 Apr 20;33(12 ):1356-63
references.pmid: 25624432
references.citation: Eur J Cancer. 2014 Apr;50(6):1090-9
references.pmid: 24485664
references.citation: J Clin Oncol. 2014 Apr 10;32(11):1143-50
references.pmid: 24590644
references.citation: Lancet. 2000 Apr 29;355(9214):1491-8
references.pmid: 10801170
references.citation: Cancer. 2009 Aug 1;115(15):3437-45
references.pmid: 19536889